The study uses zirconium-89 PET imaging to inform doses of an actinium-225 therapy and targets disease with low or absent prostate-specific membrane antigen (PSMA) expression.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.